Literature DB >> 25014508

Terminalia arjuna in coronary artery disease: ethnopharmacology, pre-clinical, clinical & safety evaluation.

Divya Kapoor1, Rajesh Vijayvergiya2, Veena Dhawan3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Terminalia arjuna (Roxb.) Wight & Arn. is one of the most popular and beneficial medicinal plants in indigenous system of medicine for the treatment of cardiovascular diseases. This comprehensive review provides latest updates on traditional use, phytochemistry, pharmacological and toxicological data, clinical efficacy and safety of Terminalia arjuna as well as outlined strategies for future research and development to scientifically validate the therapeutic potential of this plant.
MATERIALS AND METHODS: Information about Terminalia arjuna was collected via a systematic electronic and library search of various indexed and non-indexed journals, some local books and varied articles published on ethnopharmacology, phytochemistry and traditional uses. Various pre-clinical (2000-2014) and clinical studies (1990-2014) have also been considered regarding efficacy and safety profile of Terminalia arjuna.
RESULTS: Evidence from various in vitro, in vivo and clinical trials reveal the pleiotropic effects of Terminalia arjuna such as anti-atherogenic, hypotensive, inotropic, anti-inflammatory, anti-thrombotic and antioxidant actions for treatment of various cardiovascular disorders. It is clearly documented that this plant has a good safety profile when used in conjunction with other conventional drugs. However, there is a paucity of data regarding the exact molecular mechanism of its action, appropriate form of drug administration, whether whole crude drug or aqueous or alcoholic extract should be used, toxicological studies and its interaction with other drugs.
CONCLUSIONS: In conclusion, this review highlights the importance as well as pleiotropic actions and functional aspects of Terminalia arjuna especially in cardiovascular diseases. Though, various pharmacological studies and clinical trials support its benefit in the CVD as per traditional use, new clinical trials using more rigorous state of the art technology and in a larger population setup are warranted to assess the traditional putative efficacy of Terminalia arjuna.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anti-atherogenic; Anti-inflammatory; Antioxidant; Arjungenin (PubChem CID: 12444386); Arjunglucoside I (PubChem CID: 49768307); Arjunic acid (PubChem CID: 15385516); Arjunolic Acid (PubChem CID: 73641); Arjunolone (PubChem CID: 14034821); Arjunten (PubChem CID: 3052779); Cardio-protective; Coronary artery disease; Cyanidin (PubChem CID: 128861); Ellagic Acid (PubChem CID: 5281855); Gallic Acid (PubChem CID: 370); Luteolin (PubChem CID: 5280445); Terminalia arjuna

Mesh:

Substances:

Year:  2014        PMID: 25014508     DOI: 10.1016/j.jep.2014.06.056

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  11 in total

1.  Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence.

Authors:  Divya Kapoor; Dimple Trikha; Rajesh Vijayvergiya; K K Parashar; Deepak Kaul; Veena Dhawan
Journal:  J Cardiovasc Transl Res       Date:  2015-04-01       Impact factor: 4.132

2.  Arjunarishta alleviates experimental colitis via suppressing proinflammatory cytokine expression, modulating gut microbiota and enhancing antioxidant effect.

Authors:  Damita Cota; Sanjay Mishra; Sushant Shengule
Journal:  Mol Biol Rep       Date:  2020-09-03       Impact factor: 2.316

3.  Terminalia arjuna prevents Interleukin-18-induced atherosclerosis via modulation of NF-κB/PPAR-γ-mediated pathway in Apo E-/- mice.

Authors:  Owais Mohammad Bhat; P Uday Kumar; K Rajender Rao; Ashfaq Ahmad; Veena Dhawan
Journal:  Inflammopharmacology       Date:  2017-05-25       Impact factor: 4.473

4.  Toxicological and hematological effect of Terminalia arjuna bark extract on a freshwater catfish, Heteropneustes fossilis.

Authors:  A Suely; H Zabed; A B A Ahmed; J Mohamad; M Nasiruddin; J N Sahu; P Ganesan
Journal:  Fish Physiol Biochem       Date:  2015-10-26       Impact factor: 2.794

Review 5.  Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A review.

Authors:  Augustine Amalraj; Sreeraj Gopi
Journal:  J Tradit Complement Med       Date:  2016-03-20

6.  Ethanolic Fraction of Terminalia tomentosa Attenuates Biochemical and Physiological Derangements in Diet Induced Obese Rat Model by Regulating Key Lipid Metabolizing Enzymes and Adipokines.

Authors:  Balaji Meriga; Parim Brahma Naidu; Ganjayi Muniswamy; Gen Hanuma Kumar; Ramavat Ravindar Naik; Suresh Pothani
Journal:  Pharmacogn Mag       Date:  2017-06-22       Impact factor: 1.085

7.  In vitro modulatory effects of Terminalia arjuna, arjunic acid, arjunetin and arjungenin on CYP3A4, CYP2D6 and CYP2C9 enzyme activity in human liver microsomes.

Authors:  Alice Varghese; Jay Savai; Nancy Pandita; Ram Gaud
Journal:  Toxicol Rep       Date:  2015-02-17

8.  Terminalia fagifolia Mart. & Zucc. elicits vasorelaxation of rat thoracic aorta through nitric oxide and K+ channels dependent mechanism.

Authors:  Emanuella F de Carvalho; André F Nunes; Náiguel C B Silva; João Paulo da Silva Gomes; Renato P de Sousa; Valdelânia G Silva; Paulo H M Nunes; Rosimeire F Santos; Mariana H Chaves; Aldeidia P Oliveira; Rita C M Oliveira
Journal:  Biol Open       Date:  2019-02-27       Impact factor: 2.422

Review 9.  Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension.

Authors:  Seyed Vahid Jasemi; Hosna Khazaei; Ina Yosifova Aneva; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

Review 10.  Plants Used as Antihypertensive.

Authors:  Tarawanti Verma; Manish Sinha; Nitin Bansal; Shyam Raj Yadav; Kamal Shah; Nagendra Singh Chauhan
Journal:  Nat Prod Bioprospect       Date:  2020-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.